These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 27553050)

  • 1. Calculation of therapeutic activity of radioiodine in Graves' disease by means of Marinelli's formula, using technetium (
    Szumowski P; Mojsak M; Abdelrazek S; Sykała M; Amelian-Fiłonowicz A; Jurgilewicz D; Myśliwiec J
    Endocrine; 2016 Dec; 54(3):751-756. PubMed ID: 27553050
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Zhao L; Zhang W; Xin Y; Wen Q; Bail L; Guan F; Bin J
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(6):349-353. PubMed ID: 30413358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome.
    Reinhardt MJ; Brink I; Joe AY; Von Mallek D; Ezziddin S; Palmedo H; Krause TM
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1118-24. PubMed ID: 12192554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between thyroid volume and humoral thyroid autoimmunity after radioiodine therapy in Graves' disease.
    Sawicka N; Sowiński J
    Endokrynol Pol; 2012; 63(1):10-3. PubMed ID: 22378091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of (99m)Tc-pertechnetate thyroid imaging on radioactive iodine uptake.
    Guo N; Yang K; Lin YS; Wang T
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2014 Jun; 36(3):267-70. PubMed ID: 24997818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The radioiodine turnover rate as a determinant of radioiodine treatment outcome in Graves' disease.
    van Isselt JW; Broekhuizen-de Gast HS
    Hell J Nucl Med; 2010; 13(1):2-5. PubMed ID: 20411161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of (99m)Tc-pertechnetate thyroid scintigraphy in radioiodine therapy in a cohort of Chinese Graves' disease patients: a pilot clinical study.
    Hou H; Hu S; Fan R; Sun W; Zhang X; Tian M
    Biomed Res Int; 2015; 2015():974689. PubMed ID: 25879041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Predictive value of thyrotropin receptor antibodies using the second generation TRAb human assay after radioiodine treatment in Graves' disease].
    Zöphel K; Wunderlich G; Kopprasch C; Koch R; Franke WG; Kotzerke J
    Nuklearmedizin; 2003; 42(2):63-70. PubMed ID: 12695788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
    Berg GE; Michanek AM; Holmberg EC; Fink M
    J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Estimation of effective half life of 131I in radioiodine therapy for Graves' disease using a single radioiodine uptake measurement].
    Watanabe M; Ito K; Mimura T; Ishikawa N; Ino E; Saitoh T; Tsuji H; Tsuchiya T
    Kaku Igaku; 1993 Sep; 30(9):1055-62. PubMed ID: 8230826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factor analysis in 325 patients with Graves' disease treated with radioiodine therapy.
    Yang D; Xue J; Ma W; Liu F; Fan Y; Rong J; Yang A; Yu Y
    Nucl Med Commun; 2018 Jan; 39(1):16-21. PubMed ID: 29040161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the factors associated with Tc-99m pertechnetate uptake in thyrotoxicosis and graves' disease.
    Kidokoro-Kunii Y; Emoto N; Cho K; Oikawa S
    J Nippon Med Sch; 2006 Feb; 73(1):10-7. PubMed ID: 16538017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orbital scintigraphy with the somatostatin receptor tracer 99mTc-P829 in patients with Graves' disease.
    Burggasser G; Hurtl I; Hauff W; Lukas J; Greifeneder M; Heydari B; Thaler A; Wedrich A; Virgolini I
    J Nucl Med; 2003 Oct; 44(10):1547-55. PubMed ID: 14530465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Influence of glucocorticoid therapy on intratherapeutic biodistribution of 131I radioiodine therapy in Graves' disease].
    Halstenberg J; Kranert WT; Korkusuz H; Mayer A; Ackermann H; Grünwald F; Happel C
    Nuklearmedizin; 2018 Apr; 57(2):43-49. PubMed ID: 29590674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
    Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
    Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of ¹³¹I therapy and correlation factors of Graves' disease patients: a 4-year retrospective study.
    Zheng W; Jian T; Guizhi Z; Zhaowei M; Renfei W
    Nucl Med Commun; 2012 Jan; 33(1):97-101. PubMed ID: 22008631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyrotoxic Graves' disease with normal thyroidal technetium-99m pertechnetate uptake.
    Ikekubo K; Hino M; Ito H; Koh T; Ishihara T; Kurahachi H; Kasagi K; Hidaka A; Mori T
    Ann Nucl Med; 1990 Jul; 4(2):43-8. PubMed ID: 2171608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?
    Kobe C; Eschner W; Wild M; Rahlff I; Sudbrock F; Schmidt M; Dietlein M; Schicha H
    Nucl Med Commun; 2010 Mar; 31(3):201-5. PubMed ID: 19907353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy dose calculation in Graves' disease using early I-123 uptake measurements.
    Vemulakonda US; Atkins FB; Ziessman HA
    Clin Nucl Med; 1996 Feb; 21(2):102-5. PubMed ID: 8697676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Impact of pretreatment variables on the outcome of standardized 131I therapy with 150 Gray in Graves' disease].
    Pfeilschifter J; Elser H; Haufe S; Ziegler R; Georgi P
    Nuklearmedizin; 1997 Apr; 36(3):81-6. PubMed ID: 9162906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.